All Regimens by Diseases
Chemotherapy Regimens
Gestational Trophoblastic Neoplasia
Sort:
- Gestational Trophoblastic NeoplasiaAvelumabINDICATIONS: High-risk disease: Multiagent chemotherapy-resistant GTN. Intermediate Trophoblastic Tumor (PSTT and ETT)Template ID:GTN20(Updated 03/29/2025)
- Gestational Trophoblastic NeoplasiaBEP (Bleomycin/Etoposide/CISplatin)INDICATIONS: High-risk disease: Methotrexate-resistant GTN. Intermediate Trophoblastic Tumor (PSTT and ETT)Template ID:GTN7(Updated 03/29/2025)
- Gestational Trophoblastic NeoplasiaCapecitabineINDICATIONS: High-risk disease: Multiagent chemotherapy-resistant GTN. Intermediate Trophoblastic Tumor (PSTT and ETT)Template ID:GTN14(Updated 03/29/2025)
- Gestational Trophoblastic NeoplasiaCISplatin/EtoposideINDICATIONS: Low-dose induction therapy: Metastatic disease (prognostic score >12) in patients at significant risk for pulmonary, intraperitoneal, or intracranial hemorrhageTemplate ID:GTN13(Updated 03/29/2025)
- Gestational Trophoblastic NeoplasiaCISplatin/GemcitabineINDICATIONS: High-risk disease: Multiagent chemotherapy-resistant GTN. Intermediate Trophoblastic Tumor (PSTT and ETT)Template ID:GTN19(Updated 03/29/2025)
- Gestational Trophoblastic NeoplasiaDACTINomycinINDICATIONS: Low-risk disease: <7 FIGO prognostic scoreTemplate ID:GTN1(Updated 03/29/2025)
- Gestational Trophoblastic NeoplasiaEMA/CO (Etoposide/Methotrexate/DACTINomycin/Cyclophosphamide/VinCRIStine)INDICATIONS: High-risk disease: ≥7 FIGO prognostic score or Stage IV - Primary treatment. Low-risk disease: <7 FIGO prognostic score - Subsequent therapyTemplate ID:GTN3(Updated 03/29/2025)
- Gestational Trophoblastic NeoplasiaEMA/EP (Etoposide/Methotrexate/DACTINomycin/Etoposide/CISplatin)INDICATIONS: High-risk disease: ≥7 FIGO prognostic score or Stage IV - Good response to EMA/CO followed by hCG plateau at low levels or Relapse from remission following EMA/CO. Low-risk disease: <7 FIGO prognostic score - Subsequent therapy. Intermediate Trophoblastic Tumor (PSTT and ETT)Template ID:GTN4(Updated 03/29/2025)
- Gestational Trophoblastic NeoplasiaEP/EMA (Etoposide/CISplatin/Etoposide/Methotrexate/DACTINomycin)INDICATIONS: High-risk disease: ≥7 FIGO prognostic score or Stage IV - Good response to EMA/CO followed by hCG plateau at low levels or Relapse from remission following EMA/CO. Low-risk disease: <7 FIGO prognostic score - Subsequent therapy. Intermediate Trophoblastic Tumor (PSTT and ETT)Template ID:GTN5(Updated 03/29/2025)
- Gestational Trophoblastic NeoplasiaGemcitabineINDICATIONS: High-risk disease: Multiagent chemotherapy-resistant GTN. Intermediate Trophoblastic Tumor (PSTT and ETT)Template ID:GTN12(Updated 03/29/2025)
- Gestational Trophoblastic NeoplasiaICE (Ifosfamide/Mesna/CARBOplatin/Etoposide)INDICATIONS: High-risk disease: Methotrexate-resistant GTN. Intermediate Trophoblastic Tumor (PSTT and ETT)Template ID:GTN10(Updated 03/29/2025)
- Gestational Trophoblastic NeoplasiaMethotrexateINDICATIONS: Low-risk disease: <7 FIGO prognostic scoreTemplate ID:GTN2(Updated 03/29/2025)
- Gestational Trophoblastic NeoplasiaNivolumabINDICATIONS: High-risk disease: Multiagent chemotherapy-resistant GTN. Intermediate Trophoblastic Tumor (PSTT and ETT)Template ID:GTN16(Updated 03/29/2025)
- Gestational Trophoblastic NeoplasiaNivolumab and hyaluronidase-nvhyINDICATIONS: Substitution for intravenous nivolumabTemplate ID:GTN22(Updated 03/29/2025)
- Gestational Trophoblastic NeoplasiaPembrolizumabINDICATIONS: High-risk disease: Multiagent chemotherapy-resistant GTN. Intermediate Trophoblastic Tumor (PSTT and ETT)Template ID:GTN17(Updated 03/29/2025)
- Gestational Trophoblastic NeoplasiaTIP (PACLitaxel/Ifosfamide/Mesna/CISplatin)INDICATIONS: High-risk disease: Methotrexate-resistant GTNTemplate ID:GTN8(Updated 03/29/2025)
- Gestational Trophoblastic NeoplasiaTP/TE (PACLitaxel/CISplatin/PACLitaxel/Etoposide)INDICATIONS: High-risk disease: Methotrexate-resistant GTN. Intermediate Trophoblastic Tumor (PSTT and ETT)Template ID:GTN6(Updated 03/29/2025)
- Gestational Trophoblastic NeoplasiaVIP (Etoposide/Ifosfamide/Mesna/CISplatin)INDICATIONS: High-risk disease: Methotrexate-resistant GTN. Intermediate Trophoblastic Tumor (PSTT and ETT)Template ID:GTN9(Updated 03/29/2025)